Emicizumab
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Emicizumab
- Emicizumab: From Hemophilia to Acquired Coagulation Factor Deficiency (Acquired Hemophilia A)
Emicizumab: From Hemophilia to Acquired Coagulation Factor Deficiency (Acquired Hemophilia A)
One-Sentence Summary
Emicizumab is a bispecific antibody originally used to treat hemophilia (hemophilia A). The TxGNN model predicts it may be effective for acquired coagulation factor deficiency, which in practice means acquired hemophilia A. The literature compiled for this report includes 2 prospective Phase 2/3 studies and 20 publications in total, although no clinical trials are registered in the data compiled.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hemophilia; symptomatic form of hemophilia in female carriers (the Singapore licence records contain no indication text) |
| Predicted New Indication | Acquired coagulation factor deficiency (best interpreted as acquired hemophilia A) |
| TxGNN Prediction Score | 99.91% (the top-ranked prediction, pseudo-von Willebrand disease, scored 99.99% but has no supporting evidence and no mechanistic rationale) |
| Evidence Level | L1 (see note in the conclusion) |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 2 |
| Recommended Decision | Proceed with Guardrails |
Note: The report focuses on the 5th-ranked prediction, acquired coagulation factor deficiency, because it is the only one of the 10 predictions with substantial evidence and a plausible mechanism. The other nine predictions are summarised at the end of the report.
Why is This Prediction Reasonable?
Emicizumab is a bispecific antibody that bridges activated factor IX and factor X. In this way it takes over the role of missing activated factor VIII. Detailed mechanism-of-action data was not available in the data compiled for this report, but the pharmacology records confirm that it binds factor IXa and factor Xa (affinity constants of about 1.52 µM and 0.98 µM, respectively).
In acquired hemophilia A, autoantibodies neutralise the patient's own factor VIII. Because emicizumab mimics factor VIII rather than being factor VIII, it is not affected by these inhibitors. The same property is why it is already used in congenital hemophilia A with inhibitors. The mechanistic link is therefore direct.
The prediction should be read narrowly. It applies to acquired hemophilia A only, and should not be extended to acquired deficiencies of other factors (such as factor V, factor X, or von Willebrand factor).
Clinical Trial Evidence
Currently no related clinical trials registered in the data compiled for this report.
Note that the literature below describes several prospective studies (AGEHA, GTH-AHA-EMI). The records for these studies were not linked to registry entries in the data compiled.
Literature Evidence
Of 20 publications, the 10 most relevant are listed. Prospective studies are listed first, followed by comparative and cohort studies, consensus statements and reviews.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 36696195 | 2023 | Phase 3 prospective study (AGEHA) | J Thromb Haemost | First prospective multicentre, open-label study of emicizumab prophylaxis in acquired hemophilia A |
| 39134043 | 2025 | Phase 3 final analysis (AGEHA) | Thromb Haemost | Final results including patients ineligible for immunosuppression and long-term prophylaxis |
| 37858328 | 2023 | Phase 2 single-arm study (GTH-AHA-EMI) | Lancet Haematol | Emicizumab protected against bleeding and allowed immunosuppression to be deferred during the first 12 weeks |
| 40795229 | 2025 | Cohort / survival analysis | Blood Adv | Two-year follow-up of GTH-AHA-EMI patients on survival benefit with postponed immunosuppression |
| 38936699 | 2024 | Comparative study | J Thromb Haemost | Emicizumab compared with immunosuppressive therapy for managing acquired hemophilia A |
| 39361769 | 2024 | Real-world cohort | Blood Adv | 62 US patients treated off-label with emicizumab (median 10 weeks) at 12 centres |
| 38049124 | 2024 | Consensus recommendations | Hamostaseologie | GTH-AHA working group recommendations on emicizumab use |
| 37276345 | 2023 | Case series | Haemophilia | Emicizumab in acquired hemophilia A, noting the absence of randomised trials |
| 39536818 | 2025 | Narrative review | J Thromb Haemost | Management approach to acquired hemophilia A in the emicizumab era |
| 40683780 | 2025 | Review | Blood Rev | Current trends in managing acquired hemophilia A |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN15576P | HEMLIBRA SOLUTION FOR INJECTION 150MG/ML | Injection, solution | Not recorded |
| SIN15577P | HEMLIBRA SOLUTION FOR INJECTION 30MG/ML | Injection, solution | Not recorded |
Both products are valid single-ingredient registrations, manufactured by Chugai Pharma Manufacturing and Samsung Biologics.
Safety Considerations
- Drug Interactions (5 records):
- Anti-inhibitor coagulant complex (aPCC): Major. Combining it with emicizumab is associated with a thrombotic microangiopathy warning.
- Recombinant antihemophilic factor (factor VIII): Moderate.
- Recombinant coagulation factor VIIa: Moderate.
- Pharmacology records also list the targets coagulation factor IX and factor X, which reflect the mechanism rather than clinical interactions.
For warnings and contraindications, please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Two prospective studies (the Phase 3 AGEHA study and the Phase 2 GTH-AHA-EMI study), plus cohort data and consensus recommendations, support emicizumab in acquired hemophilia A, and the mechanism is directly relevant. The L1 label reflects the strength of the published prospective evidence. Strictly, it is not met by the usual criterion of two completed Phase 3 RCTs, because the studies are single-arm and no registered trials were linked. The Singapore licences also carry no acquired hemophilia A indication, so use would be off-label.
To proceed, the following is needed:
- Package insert warnings and contraindications (not yet obtained)
- Mechanism-of-action data from DrugBank
- Linking of the AGEHA and GTH-AHA-EMI studies to their registry entries
- Confirmation of the approved indication text for the Singapore licences
- A safety plan covering thrombotic events, especially avoiding concurrent aPCC use
- Clinical judgement on how emicizumab fits alongside immunosuppression
Other Predictions (All Hold)
The other nine predictions are not supported and should be held.
| Predicted Indication | Score | Reason | |------|------|------| | Pseudo-von Willebrand disease | 99.99% | Platelet disorder; no mechanistic link; no evidence | | Primary release disorder of platelets | 99.99% | Platelet secretion defect; no mechanistic link | | Glanzmann thrombasthenia | 99.98% | Platelet aggregation defect; the only article concerns a different drug (rFVIIa); likely a graph artefact | | Scott syndrome | 99.92% | Impaired phosphatidylserine exposure may limit emicizumab's action | | Bleeding diathesis due to a collagen receptor defect | 99.86% | Primary haemostasis defect, unrelated to the target step | | Hemorrhagic disorder due to constitutional thrombocytopenia | 99.85% | Does not correct platelet number | | Thrombotic thrombocytopenic purpura | 99.61% | Prothrombotic condition; mechanistically a safety concern | | Fetal and neonatal alloimmune thrombocytopenia | 99.52% | Different pathway | | "Flood factor deficiency" | 99.40% | Ambiguous name, possibly a data-entry error |
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.